{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:44:23Z","timestamp":1792453463396,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"DOI":"10.7759\/cureus.25495","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T15:10:25Z","timestamp":1653923425000},"source":"Crossref","is-referenced-by-count":22,"title":["Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease"],"prefix":"10.7759","author":[{"given":"Gashaw","family":"Hassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizeshwork","family":"Belete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"De la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesis P","family":"Camacho-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsuh K","family":"Dargie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keila G","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadesse","family":"Alemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebiyou","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee QM","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013, 10:330-44. 10.1038\/nrgastro.2013.41","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and\u00a0the\u00a0heart: JACC state-of-the-art review","volume":"73","author":"Stahl EP","year":"2019","unstructured":"Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and\u00a0the\u00a0heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 73:948-63. 10.1016\/j.jacc.2018.11.050","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i3.607","article-title":"Staging of liver fibrosis or cirrhosis: the role of hepatic venous pressure gradient measurement","volume":"7","author":"Suk KT","year":"2015","unstructured":"Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: the role of hepatic venous pressure gradient measurement. World J Hepatol. 2015, 7:607-15. 10.4254\/wjh.v7.i3.607","journal-title":"World J Hepatol"},{"key":"ref4","article-title":"Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome","volume":"75","author":"Kim CH","year":"2008","unstructured":"Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008, 75:721-8.","journal-title":"Cleve Clin J Med"},{"key":"ref5","unstructured":"About metabolic syndrome. (2021). Accessed. April 23, 2022:  https:\/\/www.heart.org\/en\/health-topics\/metabolic-syndrome\/about-metabolic-syndrome."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili K","year":"2021","unstructured":"Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021, 50:101122. 10.1016\/j.molmet.2020.101122","journal-title":"Mol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti E","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016, 65:1038-48. 10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i16.4079","article-title":"Nonalcoholic fatty liver disease as a multi-systemic disease","volume":"22","author":"Fotbolcu H","year":"2016","unstructured":"Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016, 22:4079-90. 10.3748\/wjg.v22.i16.4079","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi ZM","year":"2021","unstructured":"Younossi ZM, Stepanova M, Ong J, et al.. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021, 19:580-9. 10.1016\/j.cgh.2020.05.064","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.316337","article-title":"Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases","volume":"126","author":"Cai J","year":"2020","unstructured":"Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res. 2020, 126:679-704. 10.1161\/CIRCRESAHA.119.316337","journal-title":"Circ Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice J","year":"2018","unstructured":"Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med. 2018, 18:245-50. 10.7861\/clinmedicine.18-3-245","journal-title":"Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16029","article-title":"Perception of non-alcoholic fatty liver disease: real-life experience from Pakistan","volume":"13","author":"Butt N","year":"2021","unstructured":"Butt N, Ali Khan M, Rai L, Hussain Channa R, Khemani H, Abbasi A. Perception of non-alcoholic fatty liver disease: real-life experience from Pakistan. Cureus. 2021, 13:e16029. 10.7759\/cureus.16029","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), andEuropean Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016, 64:1388-402. 10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu S","year":"2016","unstructured":"Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016, 6:33386. 10.1038\/srep33386","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher G","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016, 65:589-600. 10.1016\/j.jhep.2016.05.013","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-3404","article-title":"Fatty liver index as a simple and useful predictor for 10-year cardiovascular disease risks determined by Framingham risk score in the general Korean population","volume":"30","author":"Chung TH","year":"2021","unstructured":"Chung TH, Kim JK, Kim JH, Lee YJ. Fatty liver index as a simple and useful predictor for 10-year cardiovascular disease risks determined by Framingham risk score in the general Korean population. J Gastrointestin Liver Dis. 2021, 30:221-6. 10.15403\/jgld-3404","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt M","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015, 61:1547-54. 10.1002\/hep.27368","journal-title":"Hepatology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100556","article-title":"Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral hepatitis B and C","volume":"27","author":"Golabi P","year":"2022","unstructured":"Golabi P, Paik JM, Eberly K, de Avila L, Alqahtani SA, Younossi ZM. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral hepatitis B and C. Ann Hepatol. 2022, 27:100556. 10.1016\/j.aohep.2021.100556","journal-title":"Ann Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.584396","article-title":"Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China","volume":"7","author":"Lin Y","year":"2020","unstructured":"Lin Y, Gong X, Li X, et al.. Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China. Front Med. 2020, 7:584396. 10.3389\/fmed.2020.584396","journal-title":"Front Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma J","year":"2017","unstructured":"Ma J, Hwang SJ, Pedley A, et al.. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017, 66:390-7. 10.1016\/j.jhep.2016.09.022","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper P","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021, 110:921-37. 10.1007\/s00392-020-01709-7","journal-title":"Clin Res Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque SM","year":"2016","unstructured":"Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol. 2016, 65:425-43. 10.1016\/j.jhep.2016.04.005","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson S","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015, 62:1148-55. 10.1016\/j.jhep.2014.11.034","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh S","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015, 13:643-54. 10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo P","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al.. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015, 149:389-97. 10.1053\/j.gastro.2015.04.043","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo P","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346:1221-31. 10.1056\/NEJMra011775","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini G","year":"2003","unstructured":"Marchesini G, Bugianesi E, Forlani G, et al.. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003, 37:917-23. 10.1053\/jhep.2003.50161","journal-title":"Hepatology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu V","year":"2010","unstructured":"Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol. 2010, 53:372-84. 10.1016\/j.jhep.2010.04.008","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1789-858. 10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2018.0557","article-title":"Arterial hypertension","volume":"115","author":"Jordan J","year":"2018","unstructured":"Jordan J, Kurschat C, Reuter H. Arterial hypertension. Dtsch Arztebl Int. 2018, 115:557-68. 10.3238\/arztebl.2018.0557","journal-title":"Dtsch Arztebl Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000532","article-title":"Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk","volume":"33","author":"Aneni EC","year":"2015","unstructured":"Aneni EC, Oni ET, Martin SS, et al.. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015, 33:1207-14. 10.1097\/HJH.0000000000000532","journal-title":"J Hypertens"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12643","article-title":"Clinical association between non-alcoholic fatty liver disease and the development of hypertension","volume":"29","author":"Ryoo JH","year":"2014","unstructured":"Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014, 29:1926-31. 10.1111\/jgh.12643","journal-title":"J Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001204","article-title":"Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies","volume":"35","author":"Bonnet F","year":"2017","unstructured":"Bonnet F, Gastaldelli A, Pihan-Le Bars F, et al.. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017, 35:493-500. 10.1097\/HJH.0000000000001204","journal-title":"J Hypertens"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32833c211b","article-title":"The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study","volume":"28","author":"Lau K","year":"2010","unstructured":"Lau K, Lorbeer R, Haring R, et al.. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens. 2010, 28:1829-35. 10.1097\/HJH.0b013e32833c211b","journal-title":"J Hypertens"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283576faf","article-title":"High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults","volume":"30","author":"Vasunta RL","year":"2012","unstructured":"Vasunta RL, Kes\u00e4niemi YA, Ylitalo AS, Ukkola OH. High ambulatory blood pressure values associated with non-alcoholic fatty liver in middle-aged adults. J Hypertens. 2012, 30:2015-9. 10.1097\/HJH.0b013e3283576faf","journal-title":"J Hypertens"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2007.03.008","article-title":"Local adipose tissue depots as cardiovascular risk factors","volume":"75","author":"Thalmann S","year":"2007","unstructured":"Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res. 2007, 75:690-701. 10.1016\/j.cardiores.2007.03.008","journal-title":"Cardiovasc Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.07.052","article-title":"A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?","volume":"230","author":"Oni ET","year":"2013","unstructured":"Oni ET, Agatston AS, Blaha MJ, et al.. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis. 2013, 230:258-67. 10.1016\/j.atherosclerosis.2013.07.052","journal-title":"Atherosclerosis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.09.002","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis","volume":"48","author":"Jaruvongvanich V","year":"2016","unstructured":"Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis. 2016, 48:1410-7. 10.1016\/j.dld.2016.09.002","journal-title":"Dig Liver Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2016.12.033","article-title":"Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis","volume":"11","author":"Mahfood Haddad T","year":"2017","unstructured":"Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla VM. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr. 2017, 11:209-16. 10.1016\/j.dsx.2016.12.033","journal-title":"Diabetes Metab Syndr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131138","article-title":"Nonalcoholic hepatic steatosis is a strong predictor of high-risk coronary-artery plaques as determined by multidetector CT","volume":"10","author":"Osawa K","year":"2015","unstructured":"Osawa K, Miyoshi T, Yamauchi K, et al.. Nonalcoholic hepatic steatosis is a strong predictor of high-risk coronary-artery plaques as determined by multidetector CT. PLoS One. 2015, 10:e0131138. 10.1371\/journal.pone.0131138","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.07.107","article-title":"Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction","volume":"120","author":"Keskin M","year":"2017","unstructured":"Keskin M, Hay\u0131ro\u011flu M\u0130, Uzun AO, G\u00fcven\u00e7 TS, \u015eahin S, Kozan \u00d6. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017, 120:1720-6. 10.1016\/j.amjcard.2017.07.107","journal-title":"Am J Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams LA","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017, 66:1138-53. 10.1136\/gutjnl-2017-313884","journal-title":"Gut"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00005","article-title":"Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis","volume":"5","author":"Mantovani A","year":"2017","unstructured":"Mantovani A. Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis. J Clin Transl Hepatol. 2017, 5:134-41. 10.14218\/JCTH.2017.00005","journal-title":"J Clin Transl Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study)","volume":"10","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki AJ","year":"2015","unstructured":"K\u00e4r\u00e4j\u00e4m\u00e4ki AJ, P\u00e4tsi OP, Savolainen M, Kes\u00e4niemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One. 2015, 10:e0142937. 10.1371\/journal.pone.0142937","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0091","article-title":"Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring","volume":"39","author":"Mantovani A","year":"2016","unstructured":"Mantovani A, Rigamonti A, Bonapace S, et al.. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care. 2016, 39:1416-23. 10.2337\/dc16-0091","journal-title":"Diabetes Care"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057183","article-title":"Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes","volume":"8","author":"Targher G","year":"2013","unstructured":"Targher G, Valbusa F, Bonapace S, et al.. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013, 8:e57183. 10.1371\/journal.pone.0057183","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0010-0","article-title":"Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease","volume":"15","author":"Anstee QM","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018, 15:425-39. 10.1038\/s41575-018-0010-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.015","article-title":"Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease","volume":"58","author":"Hallsworth K","year":"2013","unstructured":"Hallsworth K, Hollingsworth KG, Thoma C, et al.. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013, 58:757-62. 10.1016\/j.jhep.2012.11.015","journal-title":"J Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.04.003","article-title":"Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"64","author":"Mantovani A","year":"2015","unstructured":"Mantovani A, Pernigo M, Bergamini C, et al.. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism. 2015, 64:879-87. 10.1016\/j.metabol.2015.04.003","journal-title":"Metabolism"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020, 73:202-9. 10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison E","year":"2019","unstructured":"Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019, 95:314-22. 10.1136\/postgradmedj-2018-136316","journal-title":"Postgrad Med J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190117102111","article-title":"Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts","volume":"24","author":"Papatheodoridi M","year":"2018","unstructured":"Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Des. 2018, 24:4574-86. 10.2174\/1381612825666190117102111","journal-title":"Curr Pharm Des"},{"key":"ref55","article-title":"Nonalcoholic fatty liver","author":"Kudaravalli P","year":"2021","unstructured":"Kudaravalli P, John S. Nonalcoholic fatty liver. StatPearls, Treasure Island (FL); 2021."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera L","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019, 156:1264-81. 10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2021.11.048","article-title":"EUS imaging for the diagnosis of nonalcoholic fatty liver disease","volume":"95","author":"Silva-Santisteban A","year":"2022","unstructured":"Silva-Santisteban A, Agnihotri A, Cruz-Romero C, et al.. EUS imaging for the diagnosis of nonalcoholic fatty liver disease. Gastrointest Endosc. 2022, 95:711-6. 10.1016\/j.gie.2021.11.048","journal-title":"Gastrointest Endosc"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v10.i8.530","article-title":"Current status of imaging in nonalcoholic fatty liver disease","volume":"10","author":"Li Q","year":"2018","unstructured":"Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018, 10:530-42. 10.4254\/wjh.v10.i8.530","journal-title":"World J Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.10091790","article-title":"Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy","volume":"256","author":"van Werven JR","year":"2010","unstructured":"van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, Stoker J. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010, 256:159-68. 10.1148\/radiol.10091790","journal-title":"Radiology"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni G","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6:33. 10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001682","article-title":"Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese","volume":"94","author":"Huang X","year":"2015","unstructured":"Huang X, Xu M, Chen Y, et al.. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine. 2015, 94:e1682. 10.1097\/MD.0000000000001682","journal-title":"Medicine"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee JH","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, et al.. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010, 42:503-8. 10.1016\/j.dld.2009.08.002","journal-title":"Dig Liver Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.62010","article-title":"Association of hepatic steatosis index and fatty liver index with carotid atherosclerosis in type 2 diabetes","volume":"18","author":"Wang C","year":"2021","unstructured":"Wang C, Cai Z, Deng X, et al.. Association of hepatic steatosis index and fatty liver index with carotid atherosclerosis in type 2 diabetes. Int J Med Sci. 2021, 18:3280-9. 10.7150\/ijms.62010","journal-title":"Int J Med Sci"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-017-0206-2","article-title":"Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults","volume":"14","author":"Dai H","year":"2017","unstructured":"Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab. 2017, 14:49. 10.1186\/s12986-017-0206-2","journal-title":"Nutr Metab"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-5-26","article-title":"The \"lipid accumulation product\" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison","volume":"5","author":"Kahn HS","year":"2005","unstructured":"Kahn HS. The \"lipid accumulation product\" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005, 5:26. 10.1186\/1471-2261-5-26","journal-title":"BMC Cardiovasc Disord"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12665","article-title":"Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Otgonsuren M","year":"2014","unstructured":"Otgonsuren M, Estep MJ, Hossain N, et al.. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol. 2014, 29:2006-13. 10.1111\/jgh.12665","journal-title":"J Gastroenterol Hepatol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14967","article-title":"Liver fat scores predict liver disease mortality in the United States population","volume":"48","author":"Unalp-Arida A","year":"2018","unstructured":"Unalp-Arida A, Ruhl CE. Liver fat scores predict liver disease mortality in the United States population. Aliment Pharmacol Ther. 2018, 48:1003-16. 10.1111\/apt.14967","journal-title":"Aliment Pharmacol Ther"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen A","year":"2009","unstructured":"Kotronen A, Peltonen M, Hakkarainen A, et al.. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009, 137:865-72. 10.1053\/j.gastro.2009.06.005","journal-title":"Gastroenterology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi Y","year":"2014","unstructured":"Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014, 20:15539-48. 10.3748\/wjg.v20.i42.15539","journal-title":"World J Gastroenterol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt EM","year":"2010","unstructured":"Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010, 16:5286-96. 10.3748\/wjg.v16.i42.5286","journal-title":"World J Gastroenterol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.008","article-title":"Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"65","author":"Brown GT","year":"2016","unstructured":"Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016, 65:1080-6. 10.1016\/j.metabol.2015.11.008","journal-title":"Metabolism"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13653","article-title":"Diagnosis of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: why liver biopsy is essential","volume":"38","author":"Bedossa P","year":"2018","unstructured":"Bedossa P. Diagnosis of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: why liver biopsy is essential. Liver Int. 2018, 38:64-6. 10.1111\/liv.13653","journal-title":"Liver Int"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v8.i2.51","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk","volume":"8","author":"Patil R","year":"2017","unstructured":"Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017, 8:51-8. 10.4291\/wjgp.v8.i2.51","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01192-4","article-title":"Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study","volume":"20","author":"Ichikawa K","year":"2021","unstructured":"Ichikawa K, Miyoshi T, Osawa K, et al.. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study. Cardiovasc Diabetol. 2021, 20:8. 10.1186\/s12933-020-01192-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref75","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos P","year":"2009","unstructured":"Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009, 13:9-19.","journal-title":"Hippokratia"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13419","article-title":"Nonalcoholic fatty liver disease: an emerging driver of hypertension","volume":"75","author":"Zhao YC","year":"2020","unstructured":"Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020, 75:275-84. 10.1161\/HYPERTENSIONAHA.119.13419","journal-title":"Hypertension"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam M","year":"2018","unstructured":"Dharmalingam M, Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018, 22:421-8. 10.4103\/ijem.IJEM_585_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021, 18:599-612. 10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos SA","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019, 92:82-97. 10.1016\/j.metabol.2018.11.014","journal-title":"Metabolism"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.02.003","article-title":"Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease","volume":"53","author":"Wu T","year":"2021","unstructured":"Wu T, Ye J, Gong X, et al.. Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. Dig Liver Dis. 2021, 53:1610-9. 10.1016\/j.dld.2021.02.003","journal-title":"Dig Liver Dis"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02288-2","article-title":"Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)","volume":"20","author":"Cho Y","year":"2022","unstructured":"Cho Y, Rhee H, Kim YE, et al.. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Med. 2022, 20:93. 10.1186\/s12916-022-02288-2","journal-title":"BMC Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/cld.1017","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease","volume":"17","author":"Przybyszewski EM","year":"2021","unstructured":"Przybyszewski EM, Targher G, Roden M, Corey KE. Nonalcoholic fatty liver disease and cardiovascular disease. Clin Liver Dis. 2021, 17:19-22. 10.1002\/cld.1017","journal-title":"Clin Liver Dis"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14569","article-title":"Weight loss interventions and nonalcoholic fatty liver disease: optimizing liver outcomes","volume":"24","author":"Finer N","year":"2022","unstructured":"Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimizing liver outcomes. Diabetes Obes Metab. 2022, 24:44-54. 10.1111\/dom.14569","journal-title":"Diabetes Obes Metab"},{"key":"ref84","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez E","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015, 149:367-78.","journal-title":"Gastroenterology"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-022-01081-x","article-title":"Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial","author":"Khodami B","year":"2022","unstructured":"Khodami B, Hatami B, Yari Z, et al.. Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial. Eur J Clin Nutr. 2022, 10.1038\/s41430-022-01081-x","journal-title":"Eur J Clin Nutr"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-019-03977-3","article-title":"An examination of who is eligible and who is receiving bariatric surgery in England: secondary analysis of the health survey for England dataset","volume":"29","author":"Desogus D","year":"2019","unstructured":"Desogus D, Menon V, Singhal R, Oyebode O. An examination of who is eligible and who is receiving bariatric surgery in England: secondary analysis of the health survey for England dataset. Obes Surg. 2019, 29:3246-51. 10.1007\/s11695-019-03977-3","journal-title":"Obes Surg"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2019.06.002","article-title":"Liver transplantation for bariatric surgery-related liver failure: a systematic review of a rare condition","volume":"15","author":"Addeo P","year":"2019","unstructured":"Addeo P, Cesaretti M, Anty R, Iannelli A. Liver transplantation for bariatric surgery-related liver failure: a systematic review of a rare condition. Surg Obes Relat Dis. 2019, 15:1394-401. 10.1016\/j.soard.2019.06.002","journal-title":"Surg Obes Relat Dis"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1159\/000523964","article-title":"Acute liver injury and acute liver failure following bariatric surgery","volume":"16","author":"van Golen RF","year":"2022","unstructured":"van Golen RF, de Waard NE, Moolenaar LR, et al.. Acute liver injury and acute liver failure following bariatric surgery. Case Rep Gastroenterol. 2022, 16:240-6. 10.1159\/000523964","journal-title":"Case Rep Gastroenterol"},{"key":"ref89","article-title":"Managing nonalcoholic fatty liver disease: recommendations for family physicians","volume":"53","author":"Grattagliano I","year":"2007","unstructured":"Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician. 2007, 53:857-63.","journal-title":"Can Fam Physician"},{"key":"ref90","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque SM","year":"2021","unstructured":"Francque SM, Marchesini G, Kautz A, et al.. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep. 2021, 3:100322.","journal-title":"JHEP Rep"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2740-8","article-title":"Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease","volume":"58","author":"Wieland AC","year":"2013","unstructured":"Wieland AC, Quallick M, Truesdale A, Mettler P, Bambha KM. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2013, 58:2809-16. 10.1007\/s10620-013-2740-8","journal-title":"Dig Dis Sci"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i2.233","article-title":"Awareness of non-alcoholic steatohepatitis and treatment guidelines: what are physicians telling us?","volume":"13","author":"Wessels DH","year":"2021","unstructured":"Wessels DH, Rosenberg Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: what are physicians telling us?. World J Hepatol. 2021, 13:233-41. 10.4254\/wjh.v13.i2.233","journal-title":"World J Hepatol"},{"key":"ref93","article-title":"Screening for nonalcoholic fatty liver disease in the primary care clinic","volume":"15","author":"Pandyarajan V","year":"2019","unstructured":"Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for nonalcoholic fatty liver disease in the primary care clinic. Gastroenterol Hepatol. 2019, 15:357-65.","journal-title":"Gastroenterol Hepatol"},{"key":"ref94","unstructured":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. (2012). Accessed. April 19, 2022: https:\/\/www.worldgastroenterology.org\/guidelines\/nafld-nash\/nafld-nash-english."},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi Z","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al.. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018, 15:11-20. 10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref96","article-title":"Case-finding strategies in non-alcoholic fatty liver disease","volume":"3","author":"Boursier J","year":"2021","unstructured":"Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep. 2021, 3:100219.","journal-title":"JHEP Rep"},{"key":"ref97","article-title":"The challenging ethical landscape of non-alcoholic fatty liver disease","author":"Berry P","year":"2022","unstructured":"Berry P, Kotha S. The challenging ethical landscape of non-alcoholic fatty liver disease. Eur Med J. 2022, 1-9.","journal-title":"Eur Med J"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus JV","year":"2022","unstructured":"Lazarus JV, Mark HE, Anstee QM, et al.. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022, 19:60-78. 10.1038\/s41575-021-00523-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani AL","year":"2008","unstructured":"Fracanzani AL, Valenti L, Bugianesi E, et al.. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008, 48:792-8. 10.1002\/hep.22429","journal-title":"Hepatology"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis JD","year":"2011","unstructured":"Lewis JD, Ferrara A, Peng T, et al.. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011, 34:916-22. 10.2337\/dc10-1068","journal-title":"Diabetes Care"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1293523","article-title":"Current and future treatment options in non-alcoholic steatohepatitis (NASH)","volume":"11","author":"Lazaridis N","year":"2017","unstructured":"Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol. 2017, 11:357-69. 10.1080\/17474124.2017.1293523","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1143","article-title":"Lean NAFLD: a not so benign condition?","volume":"2","author":"VanWagner LB","year":"2018","unstructured":"VanWagner LB, Armstrong MJ. Lean NAFLD: a not so benign condition?. Hepatol Commun. 2018, 2:5-8. 10.1002\/hep4.1143","journal-title":"Hepatol Commun"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases - U.S. Food and Drug Administration joint workshop","volume":"61","author":"Sanyal AJ","year":"2015","unstructured":"Sanyal AJ, Friedman SL, McCullough AJ, Dimick L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases - U.S. Food and Drug Administration joint workshop. Hepatology. 2015, 61:1392-405. 10.1002\/hep.27678","journal-title":"Hepatology"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2017.11929552","article-title":"Improving health outcomes through patient education and partnerships with patients","volume":"30","author":"Paterick TE","year":"2017","unstructured":"Paterick TE, Patel N, Tajik AJ, Chandrasekaran K. Improving health outcomes through patient education and partnerships with patients. Proc (Bayl Univ Med Cent). 2017, 30:112-3. 10.1080\/08998280.2017.11929552","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref105","unstructured":"Nonalcoholic fatty liver disease (NAFLD) & NASH. ( 2022). Accessed. April 19, 2022: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash."},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.1240","article-title":"My doctor told me I have fatty liver-what do I need to know?","volume":"179","author":"Aby ES","year":"2019","unstructured":"Aby ES, Benhammou JN, Tabibian JH. My doctor told me I have fatty liver-what do I need to know?. JAMA Intern Med. 2019, 179:1308. 10.1001\/jamainternmed.2019.1240","journal-title":"JAMA Intern Med"},{"key":"ref107","unstructured":"Non-alcoholic fatty liver disease (NAFLD). (2022). Accessed. April 19, 2022: https:\/\/gi.org\/topics\/fatty-liver-disease-nafld\/."},{"key":"ref108","unstructured":"Tom's NAFLD\/NASH story. (2020). Accessed. May 1, 2022: https:\/\/liverfoundation.org\/toms-nafld-nash-story\/."},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10696","article-title":"Testing for nonalcoholic fatty liver disease","volume":"322","author":"Juo YY","year":"2019","unstructured":"Juo YY, Livingston EH. Testing for nonalcoholic fatty liver disease. JAMA. 2019, 322:1836. 10.1001\/jama.2019.10696","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96534-nonalcoholic-fatty-liver-disease-an-emerging-modern-day-risk-factor-for-cardiovascular-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:36:09Z","timestamp":1707489369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96534-nonalcoholic-fatty-liver-disease-an-emerging-modern-day-risk-factor-for-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":109,"URL":"https:\/\/doi.org\/10.7759\/cureus.25495","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,30]]}}}